According to the law firm press release, Kobe Steel is one of Japan's largest steel manufacturers and a major supplier of aluminum and copper products.

According to the law firm press release, Credit Suisse is a multinational financial services holding company with one of its four primary divisions focused on investment banking. The Company is based in Switzerland with its principal U.S. offices in New York, New York.

According to the Complaint, Aqua Metals was purportedly formed to engage in the business of recycling lead through a novel process called "AquaRefining." The Company claims that it has focused its efforts on developing and testing the AquaRefining process, developing a business plan, raising working capital, and developing its initial lead acid battery, or LAB, recycling facility in the Tahoe Regional Industrial Center, in McCarran, Nevada.

According to the law firm press release, Qudian is a Chinese provider of online micro-lending credit products. The Complaint charges Qudian, certain of its officers and directors, and the underwriters (collectively, the "Defendants") of the IPO with violations of the Securities Act.

According to the Complaint, OSI purportedly designs and manufactures specialized electronic systems and components. The Company claims that it sells its products and provides related services in diversified markets, including homeland security, healthcare, defense, and aerospace.

According to the law firm press release, Katanga, through its subsidiary, Kamoto Copper Company SA, engages in the copper and cobalt mining and related activities in the Democratic Republic of Congo. The Company is incorporated in Bermuda and its head office is located in Baar, Switzerland.

According to the law firm press release, this action arises from the merger between Towers and Willis (the "Merger"), which closed on January 4, 2016. The Complaint alleges that, in connection with the Merger, Defendants violated provisions of the Exchange Act by issuing false and misleading statements in proxy materials filed with the SEC. Prior to the Merger, Towers was a leading global consulting company that helped organizations improve performance through risk management, human resources, actuarial and investment services. Willis, which was based in London, was a multinational risk advisor, insurance brokerage, and reinsurance brokerage company.

Array is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's lead cancer drug binimetinib (MEK162) was evaluated in multiple trials and combinations, including a Phase 3 "NEMO" study versus dacarbazine in unresectable or metastatic NRAS-mutant melanoma patients.

Tivity Health is a fitness program provider focused on targeted population health for people aged 50 and older. The company operates three main programs: SilverSneakers senior fitness, Prime fitness and WholeHealth Living. The SilverSneakers program is offered to members of Medicare Advantage, Medicare Supplement, and Group Retiree plans through a fitness network comprised of approximately 16,000 locations.

According to the Complaint, Omega is purportedly a self-administered real estate investment trust ("REIT") that invests in income producing healthcare facilities, including long-term care facilities located in the United States and the United Kingdom.

According to the law firm press release, Endo International plc provides specialty healthcare solutions. The Company develops, manufactures, markets, and distributes pharmaceutical products and generic drugs. Endo International offers its products to the medical and healthcare industries around the globe.

According to the law firm press release, on October 20, 2017, the Company disclosed quarterly results for the third quarter 2017, disclosing earnings per share ("EPS") of $0.29, falling below earnings estimates of $0.49 per share. The Company also lowered 2017 earnings expectations, lowering EPS to $1.05-$1.10 from $1.60-$1.70.

According to the Law Firm press release, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Navient engaged in deceptive practices to facilitate the origination of subprime loans; (2) Navient committed unfair and deceptive acts by steering student borrowers into payment plans that postponed bills, allowing interest to accumulate, rather than helping them enroll in income-driven repayment plans; and (3) as a result, Navient's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

According to the law firm press release, SCANA is a $7.3 billion energy-based holding company headquartered in Cayce, S.C. SCANA is principally engaged, through its subsidiaries, in regulated electric and natural gas utility operations in South Carolina, North Carolina and Georgia. Over the past decade, SCANA has spent more than $9 billion on a project to build two nuclear reactors at the V.C. Summer Nuclear Station in South Carolina (the "Nuclear Project"). Despite this massive expenditure – financed by public investors as well as by raising customers' electrical rates nine times – SCANA recently announced that it would abandon the Nuclear Project. Evidence then came to light that, for at least the prior 18 months, SCANA appeared to know of severe problems plaguing the Nuclear Project.

According to the law firm press release, the complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements by failing to disclose: (1) that the Company acquired a substantial number of non-paying accounts as part of its acquisition of the wireline operations of Verizon Communications, Inc.; (2) that, as a result, the Company would be required to increase its reserves, and write off amounts from accounts receivable associated with the non-paying accounts; and (3) that, as a result of the foregoing, Defendants' statements about Frontier's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

According to the law firm press release, the lawsuit alleges defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Zillow's co-marketing program did not comply with the Real Estate Settlement Procedures Act; and (2) as a result, Zillow's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

According to the law firm's press release, the lawsuit alleges defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Health Insurance Innovations' application for a third-party insurance administrators license with the Florida Office of Insurance Regulation was denied due in part to material errors and omissions; (2) the Florida Office of Insurance Regulation's rejection of Health Insurance Innovations' application for a third-party insurance administrators license could result in its losing licenses in the other states; and (3) as a result, Health Insurance Innovations' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

According to the law firm press release, the lawsuit alleges defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy's lacked an effective corporate quality system; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

According to the law firm press release, Depomed, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. Among other drugs, Depomed's portfolio includes the opioids Nucynta (tapentadol) and Lazanda (fentanyl).

According to the law firm press release, the filed complaint charges that Blue Apron violated the Securities Act of 1933 because the Registration Statement failed to disclose that: rather than continue to significantly increase spending on advertising, Blue Apron had already decided to significantly reduce spending on advertising in Q2 2017, which would hurt sales and profit margins in future quarters; that Blue Apron was already experiencing adverse on-time in-full rates, meaning orders were not arriving on time or with all the ingredients needed, which was hurting customer retention; and that the Company had run into delays in Q2 2017 with its new factory in Linden, New Jersey. Subsequent to the IPO, Blue Apron's stock declined immediately, declining below $5 per share less than two months after the IPO on June 28, 2017 — a decline of 50% from the $10 per share IPO price.